Cardiopulmonary Oxygenator Market Size & Share Statistics 2028

[Research Report] The global cardiopulmonary oxygenator market is expected to grow from US$ 716.21 million in 2022 to US$ 904.15 million by 2028; it is anticipated to record a CAGR of 4.0% from 2022 to 2028.

In 2022, North America held the major market share, with the US being the largest contributor to the market in this region. The market growth is ascribed to the rising prevalence of cardiovascular and respiratory disorders, which has increased the incidence of cardiopulmonary disorders such as COPD, chronic bronchitis, and congestive heart failure. For instance, as per American Lung Association, ~12.5 million people were diagnosed with COPD, chronic bronchitis, and emphysema in the US in 2020. Moreover, the rising prevalence and incidences of such disorders have increased the number of surgical procedures among a large patient population, which has fueled the cardiopulmonary oxygenator market growth. For instance, as per a study published by the lifespan health system, ~500,00 open heart surgeries are performed in the US every year. Additionally, an increase in the prevalence of respiratory failure and infectious diseases is further expected to create demand the cardiopulmonary oxygenators demands in the coming years. 

Furthermore, the rising prevalence of cardiovascular disorders is the leading cause of death on the global level, and oxygenators can be of great assistance in lifesaving emergency cases. As per the World Health Organization, ~17.9 million lives are lost due to CVDs annually. Moreover, favorable reimbursement policies are also expected to create ample opportunities for the cardiopulmonary oxygenators market growth in the coming years. Therefore, the rising prevalence and incidence of cardiopulmonary disorders are expected to drive the cardiopulmonary oxygenator market growth during the forecast period.

Cardiopulmonary Oxygenator Market -

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Cardiopulmonary Oxygenator Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Use of Portable ECMO Device Accelerates Cardiopulmonary Oxygenation Market Growth.

The first ECMO technology was introduced in more than 60 years. The first marketed model was huge in size and shape. With the introduction of a portable version of the ECMO system, doctors are now feeling at ease while treating patients suffering from chronic COPD or heart failure. The new portable technology is revolutionary due to its compact size; it is also an ideal choice in left ventricular assist device (LVAD) therapy or lung transplant. The portable machine gives the physician enough time to access the patient's organ situation. Small portable machines are beneficial for patients undergoing more than one organ transplant. Thus, portable ECMO machines are emerging as a futuristic trend in the cardiopulmonary oxygenators market.  Some ECMO systems are intended for intra-hospital transport, while some are meant for inter-hospital patient transport. The new Capiox NX19 oxygenator helps minimize the impact of cardiopulmonary bypass by reducing hemodilution, minimizing inflammatory response, and aiding highly efficient gaseous microemboli (GME) removal.

Market Insights – Cardiopulmonary Oxygenator Market

Based on region, the market cardiopulmonary oxygenator market is segmented into North America, Europe, Asia Pacific, South America, and the Middle East & Africa. North America dominated the cardiopulmonary oxygenator market share in 2022. The market in this region is further segmented into the US, Canada, and Mexico. The North America cardiopulmonary oxygenator market growth is ascribed due to the rising prevalence of cardiovascular and respiratory disorders in the region. This has increased the incidence of cardiopulmonary disorders such as COPD, chronic bronchitis, and congestive heart failure. For instance, as per American Lung Association, ~12.5 million people were diagnosed with COPD, chronic bronchitis, and emphysema in the US in 2020. Therefore, rising prevalence and incidence of cardiopulmonary disorders are expected to drive the cardiopulmonary oxygenator market growth during the forecast period.

Product-Based Insights

Based on product, the cardiopulmonary oxygenators market is bifurcated into membrane oxygenator and bubble oxygenator. The membrane oxygenator segment held a larger market share in 2022 and is anticipated to register a higher CAGR during the forecast period (2022–2028). Technological advanced membrane oxygenators are expected to drive the cardiopulmonary oxygenator market growth during the forecast period.

The cardiopulmonary oxygenators market is segmented on the basis of product, application, type, age group, and end use. Based on product, the cardiopulmonary oxygenators market is bifurcated into bubble oxygenator and membrane oxygenator. In terms of application, the cardiopulmonary oxygenators market is bifurcated into cardiac and respiratory. Based on type, the market is bifurcated into disposable cardiopulmonary oxygenator and reusable cardiopulmonary oxygenator. Based on age group, the cardiopulmonary oxygenators market is segmented into adults, pediatric, and neonates. Based on end use, the cardiopulmonary oxygenators market is segmented into hospitals and clinics, ambulatory surgical centers, and others. Based on geography, the cardiopulmonary oxygenators market is primarily segmented into North America, Europe, Asia Pacific (APAC), the Middle East & Africa (MEA), and South America (SAM).

Cardiopulmonary Oxygenator Market Regional Insights

The regional trends and factors influencing the Cardiopulmonary Oxygenator Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Cardiopulmonary Oxygenator Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Cardiopulmonary Oxygenator Market Report Scope

Cardiopulmonary Oxygenator Market Players Density: Understanding Its Impact on Business Dynamics

The Cardiopulmonary Oxygenator Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the Cardiopulmonary Oxygenator Market are:

1. Getinge AB
2. LivaNova Plc
3. Medtronic Plc
4. Terumo Corp
5. Eurosets SRL

Disclaimer: The companies listed above are not ranked in any particular order.

The major market players operating in the cardiopulmonary oxygenators market are Getinge AB, LivaNova Plc, Medtronic Plc, Terumo Corp, Eurosets SRL, Nipro Medical Corp, Fresenius Medical Care AG & Co. KGaA, MicroPort Scientific Corp, Braile Biomédica Industry, Commerce and Representations Ltd, and Chalice Medical Ltd.

Cardiopulmonary oxygenator market players mainly focus on product approval and company expansion to create customer value.

• In Nov 2022, LivaNova PLC announced it received 510(k) clearance for extracorporeal membrane oxygenation (ECMO) from the US Food and Drug Administration (FDA) for LifeSPARC, the Company’s next-generation Advanced Circulatory Support (ACS) pump and controller system.
• In Feb 2022, Fresenius Medical Care announced that the US Food and Drug Administration (FDA) had cleared Novalung, a heart and lung support system for the treatment of acute respiratory or cardiopulmonary failure. Novalung is the first extracorporeal membrane oxygenation (ECMO) system to be cleared for more than six hours of use as extracorporeal life support.
• In Dec 2020, Nipro Medical Corp announced that Nipro Australia PTY LTD, its consolidated subsidiary, had established a sales office in Melbourne, Victoria, Australia.